Debs Lab

California Pacific CURRENTS: The online journal of CPMC Research Institute

anti-PECAM-1 monoclonal antibody therapy
The images above show that the new anti-PECAM-1 monoclonal antibody therapy Dr. Debs and colleagues are developing dramatically reduces the advanced, now lethal stages of cancer metastasis.
Overview

Most common, complex illnesses are caused by alterations in normal DNA sequencing. The Debs lab is focused on isolating the genetic flaw and then delivering a specifically targeted, corrective gene with new coding instructions—the essence of gene therapy. We are developing gene delivery systems for cancer, heart disease, cystic fibrosis, and neurodegenerative diseases including Alzheimer’s.

As part of a new CPMCRI collaborative effort, our lab is helping create a novel strategy for treating metastatic tumors with targeted, combination therapies.

Lead Investigator
Lab Members
Jennifer Wong
Pre-medical student

 

Current Projects
  • Combination therapies for metastatic cancers
    • Advanced, currently untreatable stages of common, non-fatal cancers
  • Gene delivery technologies for cancer, heart disease, and neurodegenerative diseases
    • Developing technologies that correct genes directly in the body